Pierre Sargis Sayad, Chief Medical Officer of Fennec Pharmaceuticals Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 168 common shares on October 31, 2026, at a price of $0, representing shares released from a prior restricted stock award.

Key Highlights

  • Reporting person: Pierre Sargis Sayad, Chief Medical Officer of Fennec Pharmaceuticals Inc.
  • Transaction date: October 31, 2026
  • Shares acquired: 168 common shares at a price of $0 (transaction code A)
  • Source of shares: Released from restriction from shares originally awarded on March 28, 2025, according to the filing
  • Beneficial ownership following transaction: 13,701 common shares held directly
  • No derivative securities were reported in this filing

Sayad's October 2026 Share Vesting at Fennec Pharmaceuticals

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Pierre Sargis Sayad, serving as Chief Medical Officer at Fennec Pharmaceuticals Inc. (NASDAQ:FENC), reported a single non-derivative transaction on October 31, 2026. The transaction involved the acquisition of 168 common shares at a stated price of $0, recorded under transaction code "A" (acquired).

The filing includes a footnote explaining that the 168 shares "represent shares released from restriction from shares awarded 3/28/2025." This indicates the transaction reflects the vesting of a portion of a prior restricted stock award rather than an open-market purchase. Following this transaction, Sayad's direct beneficial ownership in Fennec Pharmaceuticals common shares totals 13,701 shares, as reported in the filing.

No derivative securities, including options, warrants, or convertible securities, were reported in Table II of this Form 4. The filing was signed by Pierre Sayad and submitted on November 2, 2026. The form was filed by one reporting person and is not an amendment to a prior filing.

What Was Disclosed

Fennec Pharmaceuticals Chief Medical Officer Pierre Sargis Sayad disclosed the vesting of 168 restricted common shares at $0 on October 31, 2026, originally awarded March 28, 2025, bringing his total direct beneficial ownership to 13,701 shares.